Abstract
Original language | English |
---|---|
Journal | Alzheimer's and Dementia |
Early online date | 2021 |
DOIs | |
Publication status | E-pub ahead of print - 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers : Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. / Verberk, Inge M. W.; Misdorp, Els O.; Koelewijn, Jannet et al.
In: Alzheimer's and Dementia, 2021.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers
T2 - Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
AU - Verberk, Inge M. W.
AU - Misdorp, Els O.
AU - Koelewijn, Jannet
AU - Ball, Andrew J.
AU - Blennow, Kaj
AU - Dage, Jeffrey L.
AU - Fandos, Noelia
AU - Hansson, Oskar
AU - Hirtz, Christophe
AU - Janelidze, Shorena
AU - Kang, Sungmin
AU - Kirmess, Kristopher
AU - Kindermans, Jana
AU - Lee, Ryan
AU - Meyer, Matthew R.
AU - Shan, Dandan
AU - Shaw, Leslie M.
AU - Waligorska, Teresa
AU - West, Tim
AU - Zetterberg, Henrik
AU - Edelmayer, Rebecca M.
AU - Teunissen, Charlotte E.
N1 - Funding Information: Inge Verberk, Els Misdorp, Jannet Koelewijn, Jana Kindermans, and Teresa Waligorska report no financial disclosures nor conflicts of interest related to the present work or outside the submitted work. Andrew Ball and Dandan Shan are employees of Quanterix Corporation, and hold Quanterix Corporation stock and stock options. Simoa assay development work associated with this study was performed at and funded by Quanterix Corporation. Andrew Ball received a National Institutes of Health (NIH) Rapid Acceleration of Diagnostics grant (RADx 5534) for development/scaling of a SARS‐CoV‐2 assay, which was paid to the institution and was not associated with this study, and resulted in two provisional patent applications. Outside the submitted work, Kaj Blennow has served as a consultant or at advisory boards for Abcam, Axon, Biogen, JOMDD/Shimadzu, Lilly, MagQu, Prothena, Roche Diagnostics, and Siemens Healthineers, and as data monitoring committee for Julius Clinical and Novartis. All payments were made to him personally. Kaj Blennow is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Jeffrey L. Dage is an employee and stockholder of Eli Lilly and Company, which also supports his costs for travel and attending of meetings. Subject matter relating to the p‐tau181 assay, methods, reagents, and/or compositions of matter set forth herein are subject to patents and/or patent applications of Eli Lilly and Company. Noelia Fandos is an employee of Araclon Biotech. Oskar Hansson has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche. Christophe Hirtz has a collaboration contract with Shimadzu European Innovation Center including a PhD thesis. Shorena Janelidze is supported by research grants from Alzheimerfonden Kockska stiftelsen Stiftelsen för Gamla Tjänarinnor, and travel grants from the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University. All payments were made to Lund University. Sungmin Kang and Ryan Lee are employees and stockholders of PeopleBio. Kristopher Kirmess, Matthew Meyer, and Tim West are employees of C2N Diagnostics. C2N has received funding in support of their assay from the following grant sources: NIH, BrightFocus Foundation, GHR Foundation. Leslie M. Shaw has grant support from NIH: NIA ADNI U19 AG024904; UPenn ADRC P30 AG010124; IIS grant support from Roche; serves on Advisory Boards for Biogen, Roche, FujiRebio, Siemens Healthineers. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809‐2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019‐0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska‐Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. Payments are made to the institution. He has served on scientific advisory boards and/or as consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx, and Red Abbey Labs. These payments were made to him personally. He has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen. Further, he is a chair of the Alzheimer's Association Global Biomarker Standardization Consortium and a chair of the Alzheimer's Association Biofluid‐Based Biomarker PIA (no payments), and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (payments made to him personally). Rebecca M. Edelmayer is a full‐time employee of the Alzheimer's Association. She serves on the external advisory board of the TREAT‐AD Consortium, NIH (2020‐Present; no payments made), and the MODEL‐AD Consortium, NIH (2019‐Present; no payments made). Charlotte Teunissen has a collaboration contract with ADx Neurosciences and Quanterix, and performed contract research for or received grants from the Alzheimer's Association for the present work, and from AxonNeurosciences, Biogen, Boehringer, Brainstorm Therapeutics, EIP Pharma, Esai, Janssen Prevention Center, Roche, Toyama and Vivoryon outside the submitted work. Research of Charlotte Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. Further, she is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes‐Strijbisfonds. Also, Charlotte Teunissen serves on the editorial board of of the , on the editorial board of and of . All funding is paid to her institution. Medidact Neurologie /Springer Neuromethods book series Alzheimer's Research and Therapy Neurology: Neuroimmunology & Neuroinflammation Funding Information: We thank all GBSC members that participated in the inventory study, and all volunteers that donated blood for our research purposes. Further, we acknowledge all beyond the authors on this paper who provided support and guidance in conducting this study, in random order and not limited to Zulaiga Hussainali (Amsterdam UMC), Lynn Boonkamp (Amsterdam UMC), Heather Snyder (Alzheimer's Association), Cristopher Weber (Alzheimer's Association), Emily A. Meyers (Alzheimer's Association), Kevin Yarasheski (C2N Diagnostics), Erik Stoops (ADx Neurosciences), Andreas Jeromin (Quanterix), Takaaki Hiraoka (Shimadzu European Innovation Center), and Robert Rissman (University of California). Part of this project is funded through the Alzheimer's Association and by Marie Curie International Training Network. Inge Verberk is supported by research grants from Gieskes‐Strijbis Fonds and Alzheimer Nederland (NL‐17004). Kaj Blennow is supported by the Swedish Research Council (#2017‐00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB‐201809‐2016615), the Swedish Alzheimer Foundation (#AF‐742881), Hjärnfonden, Sweden (#FO2017‐0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‐agreement (#ALFGBG‐715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019‐466‐236), and the National Institute of Health (NIH), USA (grant #1R01AG068398‐01). Oskar Hansson is supported by the Swedish Research Council (2016‐00906), the Knut and Alice Wallenberg foundation (2017‐0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF‐939932), the Swedish Brain Foundation (FO2019‐0326), The Parkinson foundation of Sweden (1280/20), the Skåne University Hospital Foundation (2020‐O000028), Regionalt Forskningsstöd (2020‐0314), and the Swedish federal government under the ALF agreement (2018‐Projekt0279). Leslie Shaw has grant support from the NIH: NIA ADNI U19 AG024904; ADRC UPenn P30 AG010124; MJFox Foundation for Parkinson's Research grant support; Roche IIS grant support. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809‐2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019‐0228), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska‐Curie grant agreement No. 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. Charlotte Teunissen is supported by the European Commission (Marie Curie International Training Network, JPND), the Dutch Research Council (ZonMW), The Weston Brain Institute, Alzheimer Netherland. Publisher Copyright: © 2021 the Alzheimer's Association
PY - 2021
Y1 - 2021
N2 - Introduction: Pre-analytical sample handling might affect the results of Alzheimer's disease blood-based biomarkers. We empirically tested variations of common blood collection and handling procedures. Methods: We created sample sets that address the effect of blood collection tube type, and of ethylene diamine tetraacetic acid plasma delayed centrifugation, centrifugation temperature, aliquot volume, delayed storage, and freeze–thawing. We measured amyloid beta (Aβ)42 and 40 peptides with six assays, and Aβ oligomerization-tendency (OAβ), amyloid precursor protein (APP)699-711, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), total tau (t-tau), and phosphorylated tau181. Results: Collection tube type resulted in different values of all assessed markers. Delayed plasma centrifugation and storage affected Aβ and t-tau; t-tau was additionally affected by centrifugation temperature. The other markers were resistant to handling variations. Discussion: We constructed a standardized operating procedure for plasma handling, to facilitate introduction of blood-based biomarkers into the research and clinical settings.
AB - Introduction: Pre-analytical sample handling might affect the results of Alzheimer's disease blood-based biomarkers. We empirically tested variations of common blood collection and handling procedures. Methods: We created sample sets that address the effect of blood collection tube type, and of ethylene diamine tetraacetic acid plasma delayed centrifugation, centrifugation temperature, aliquot volume, delayed storage, and freeze–thawing. We measured amyloid beta (Aβ)42 and 40 peptides with six assays, and Aβ oligomerization-tendency (OAβ), amyloid precursor protein (APP)699-711, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), total tau (t-tau), and phosphorylated tau181. Results: Collection tube type resulted in different values of all assessed markers. Delayed plasma centrifugation and storage affected Aβ and t-tau; t-tau was additionally affected by centrifugation temperature. The other markers were resistant to handling variations. Discussion: We constructed a standardized operating procedure for plasma handling, to facilitate introduction of blood-based biomarkers into the research and clinical settings.
KW - Alzheimer's disease
KW - amyloid beta
KW - plasma biomarkers
KW - pre-analytics
KW - stability
KW - tau
UR - http://www.scopus.com/inward/record.url?scp=85120090019&partnerID=8YFLogxK
U2 - 10.1002/alz.12510
DO - 10.1002/alz.12510
M3 - Article
C2 - 34845818
SN - 1552-5260
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
ER -